Alpha Teknova, Inc. (TKNO): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$10.63M
Year ended 2025-12-31
-$9.47M
Trailing 12 months to 2026-06-30
$6.71M2020-12-31: $6.71M2021-12-31: -$9.12M2022-12-31: -$46.49M2023-12-31: -$29.90M2024-12-31: -$19.57M2025-12-31: -$10.63M-$10.63M
2020-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$10.63Mn/m2026-03-02, From 2025-01-01
2024-12-31-$19.57Mn/m2026-03-02, From 2024-01-01
2023-12-31-$29.90Mn/m2025-03-07, From 2023-01-01
2022-12-31-$46.49Mn/m2024-03-27, From 2022-01-01
2021-12-31-$9.12Mn/m2023-03-30, From 2021-01-01
2020-12-31$6.71Mn/a2022-03-18, From 2020-01-01

EBITDA at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Alpha Teknova, Inc. (TKNO)2025-12-31-$10.63Mn/m
Immucell Corp (ICCC)2025-12-31$4.43M+306.8%
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$431.22Mn/m
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.80Mn/m
Biomerica Inc (BMRA)2026-05-31-$5.24Mn/m
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31-$48.93Mn/m
Myriad Genetics Inc (MYGN)2025-12-31-$333.50Mn/m
Neogen Corp (NEOG)2026-05-31$94.70Mn/m
Volitionrx Ltd (VNRX)2025-12-31-$20.75Mn/m

Compare TKNO, ICCC, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗